Scribe, Sanofi expand research collaboration
Genetic medicines company Scribe Therapeutics has expanded its collaboration with Sanofi to advance the development of a new wave of in vivo treatments for sickle cell disease (SCD) and other disorders. The collaboration leverages Scribe’s proprietary CRISPR X-Editing technologies and Sanofi’s targeted non-viral delivery technologies for the…